Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study

Immuno-oncology (IO) combination therapy is utilized as a first-line systemic treatment for advanced renal cell carcinoma. However, evidence supporting the use of cabozantinib after IO combination therapy is lacking. We retrospectively analyzed patients who received second-line cabozantinib after IO...

Descripción completa

Detalles Bibliográficos
Autores principales: Sazuka, Tomokazu, Matsushita, Yuto, Sato, Hiroaki, Osawa, Takahiro, Hinata, Nobuyuki, Hatakeyama, Shingo, Numakura, Kazuyuki, Ueda, Kosuke, Kimura, Takahiro, Takahashi, Masayuki, Tanaka, Hajime, Kawasaki, Yoshihide, Kurahashi, Toshifumi, Kato, Takuma, Fujita, Kazutoshi, Miyake, Makito, Kojima, Takahiro, Kitamura, Hiroshi, Miyake, Hideaki, Ichikawa, Tomohiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667220/
https://www.ncbi.nlm.nih.gov/pubmed/37996622
http://dx.doi.org/10.1038/s41598-023-48087-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667220/
https://www.ncbi.nlm.nih.gov/pubmed/37996622
http://dx.doi.org/10.1038/s41598-023-48087-4

Ejemplares similares